EFTA02572585

From: Masha Drokova Sent: Friday, November 3, 2017 3:13 AM To: Steven Sinofsky Cc: Jeffrey E. Subject: Re: Thank you for the comprehen=ive feedback Steven. For me the main value is that the system is an order=of magnitude cheaper than existing technologies, premised on leveraging dat= to help users see what daily elements are affecting their blood sugar, and=predicting dangerous highs and lows before they happen so they can take act=ons beforehand. To date, their beta app has lowered blood sugar averages in over 5=% of users 2x better than the world's most prescribed diabetes drug, Metfor=in. Which means that with the help of the date diabetes would need to use l=ss drugs. However I'd agree on complexity of regulations and saturation on the mar=et. I run Day One Ventures fund and b=sed in San Francisco. I'd be happy to connect in person sometime to learn a=out about your experience and tell about our investments and opportunities l=see. On Nov 2, 2017, at 3:24 PM, Steven Sinofsky < > wrote: <=r> Greetings Masha, <=iv> I apologize for the delay. I was at some events in i= UK where I did not have connectivity. I have work=d on a related portfolio company so I will have to be a bit abstract on the=specifics of this opportunity. So please excuse these brief thoughts.=Also, the only information I had was what was provided in your mail which w=s limited relative to any detailed analysis. * In g=neral the challenge with glucose measurement is the finger prick. Any devic= that relies on this will only be marginally better than any other device, w=ether or not there is software or a slightly more convenient measuring devi=e. This is a statement about the inconvenience of a prick (and long term ch=llenges) but also the medical challenges on relying on that point in time.<=div> * My sense is that going down the path of an innovation, that stil= has a prick, but requires a level of FDA approval is a difficult one to ap=roach. * This is a very crowded space. There are a lot of apps, a=lot of measuring devices, a lot of mixtures of app and measuring devices. 1= is very difficult to avoid appearing as a commodity to consumers. * While I understand there is potential to see innovation using novel appr=aches to analysis of data, it is not clear to me how much better the approa=h can be for an individual with data. * The real opportunity I mi=ht see is around measuring glucose or some related telemetry to assist in c=mpliance that is outside the scope of a finger prick and measuring glucose d=rectly. It seems like we should have some other data point upon which to ap=ly machine learning. I hope this helps...any frien= of JE is a friend of mine. EFTA_R1_01742258 EFTA02572585 On Nov 1, 2017, at 4:43 PM, Masha=Drokova wrote: Th=nk you Jeffrey. Steve, great meeting you. Would appreciate y=ur feedback On Nov 1, 2017, at 9:31 AM, Jeffrey E. <=a href="mailto:[email protected]">[email protected]> wrote= steve can you=give some guidance On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova <mailto: > wrote: https://drive.google.com/file/d/095O9303IJArEbXBsdll4elVob0U/=wbr>view <=pan>Center Health is building a= Al-based glucose monitoring system for the 1 in 11 Americans who suff=r from diabetes, based on machine learning and their personalized Al, =ria. Users subscribe to their disposable test strips, a $14B/yr US market, w=ich are delivered monthly, as Aria learns about their diabetes and prompts b=havioral changes to lower blood sugar. The system is an order of m=gnitude cheaper than existing technologies, premised on leveraging data to h=lp users see what daily elements are affecting their blood sugar, and p=edicting dangerous highs and lows before they happen. </=iv> Pros — Existing glucometers from big companies=are very old-fashioned and outdated, those companies make their revenue fro= overpriced strips — Direct competitors, such as =/span>iHealth and Dario have negative customer reviews and minor —&=bsp;Uses FDA-approved circuits to get the approval in an automated manner</=ont> =i>Cons — Enormous pr=ssure both from the industry players and companies such as Apple and Google=that try to develop non-invasive glucose monitoring that will wipe out test=strip products <=ont face="Roboto-Regular">— Hardware startup without a product to=sell yet, finalizing the development — Young team = 2 EFTA_R1_01742259 EFTA02572586 please not= The information contained in this communication is confidential= may be attorney-client privileged, may constitute inside information, a=d is intended only for the use of the addressee. It is the property °DEE Unauthorized use, disclosure or copying of this communication or=any part thereof is strictly prohibited and may be unlawful. If you have=received this communication in error, please notify us immediately by [email protected] <mailto:[email protected]> , and destroy this communication a=d all copies thereof, including all attachments. copyright -all rights r=served 3 EFTA_R1_01742260 EFTA02572587